FDA

News

FDA still sceptical about Intercept’s NASH drug

Intercept Pharma’s hope that its OCA candidate could become the first FDA-approved drug to treat non-alcoholic steatohepatitis (NASH) is starting to look decidedly faint.

Market Access

The future of biomedical research is animal-free

Despite the subtle change and lack of immediate impact on patients, the FDA Modernization Act 2.0 is anything but inconsequential, as Pepper Bio's Samantha Dale explains

News

FDA sets out its thinking on decentralised clinical trials

The FDA has issued draft guidance on the use of decentralised clinical trials (DCTs), which are increasingly being used by the pharma industry to tackle issues, such as di

News

Supreme Court presses pause on mifepristone curbs

The US Supreme Court has said it will allow the abortion pill mifepristone to remain available while an appeal of the decision to strike down its regulatory approval make

News

SCOTUS blocks restrictions on abortion pill mifepristone

In the latest twist and turn of the rancorous abortion pill battle in the US, the Supreme Court has temporarily halted a lower court ruling that would have restricted acce

News

Appeals court keeps abortion pill available, for now

A federal appeals court has ruled that abortion drug mifepristone can remain available, but has blocked the drug from being sent to patients in the mail, along with other

FDA still sceptical about Intercept’s NASH drug

The future of biomedical research is animal-free

FDA sets out its thinking on decentralised clinical trials

Supreme Court presses pause on mifepristone curbs

SCOTUS blocks restrictions on abortion pill mifepristone

Appeals court keeps abortion pill available, for now

CDC panel votes to scrap hepatitis B birth dose advice

How to meet your physicians where they are online

FDA

Editor's Picks